Mast cells as rapid innate sensors of cytomegalovirus by TLR3/TRIF signaling-dependent and -independent mechanisms

Cellular and Molecular Immunology

Volumn 12, Issue 2, 2015, Pages 192-201

  Becker, Marc ^a   Lemmermann, Niels A W ^a   Ebert, Stefan ^a   Baars, Pamela ^a   Renzaho, Angelique ^a   Podlech, Jürgen ^a   Stassen, Michael ^a   Reddehase, Matthias J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

cytomegalovirus; innate immunity; mast cell specific Cre recombination; mast cells; TLR3 TRIF signaling

Indexed keywords

CD8 ANTIGEN; CRE RECOMBINASE; ENHANCED GREEN FLUORESCENT PROTEIN; RANTES; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; INTEGRASE; TICAM-1 PROTEIN, MOUSE; TLR3 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GENETIC RECOMBINATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LUNG ALVEOLUS EPITHELIUM; LUNG INTERSTITIUM; MAST CELL; MAST CELL DEGRANULATION; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TARGET CELL; VIRUS REPLICATION; ANIMAL; C57BL MOUSE; FEMALE; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; MALE; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

CYTOMEGALOVIRUS; MURINAE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; INTEGRASES; KILLER CELLS, NATURAL; MACROPHAGES; MALE; MAST CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TOLL-LIKE RECEPTOR 3;

EID: 84938560823     PISSN: 16727681     EISSN: 20420226     Source Type: Journal    
DOI: 10.1038/cmi.2014.73     Document Type: Article

References (52)

1. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010; 10: 440-452.
2. Collington SJ, Williams TJ, Weller CL. Mechanisms underlying the localisation of mast cells in tissues. Trends Immunol 2011; 32: 478-485.
3. Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. Nat Rev Immunol 2014; 14: 478-494.
4. Rodewald HR, Feyerabend TB. Widespread immunological functions of mast cells: fact or fiction? Immunity 2012; 37: 13-24.
5. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012; 18: 693-704.
6. Pennock JL, Grencis RK. The mast cell and gut nematodes: damage and defence. Chem Immunol Allergy 2006; 90: 128-140.
7. Galli SJ, Maurer M, Lantz CS. Mast cells as sentinels of innate immunity. Curr Opin Immunol 1999; 11: 53-59.
8. Stassen M, Hultner L, Schmitt E. Classical and alternative pathways of mast cell activation. Crit Rev Immunol 2002; 22: 115-140.
9. Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004; 173: 531-541.
10. Kulka M, Metcalfe DD. TLR3 activation inhibits human mast cell attachment to fibronectin and vitronectin. Mol Immunol 2006; 43: 1579-1586.
11. Sandig H, Bulfone-Paus S. TLR signaling in mast cells: common and unique features. Front Immunol 2012; 3: 185.
12. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23: 749-786.
13. Hershko AY, Rivera J. Mast cell and T cell communication; amplification and control of adaptive immunity. Immunol Lett 2010; 128: 98-104.
14. Valitutti S, Espinosa E. Cognate interactions between mast cells and helper T lymphocytes. Self Nonself 2010; 1: 114-122.
15. Orinska Z, Bulanova E, Budagian V, Metz M, Maurer M, Bulfone-Paus S. TLR3-induced activation of mast cells modulates CD81 T-cell recruitment. Blood 2005; 106: 978-987.
16. St John AL, Rathore AP, Yap H, Ng ML, Metcalfe DD, Vasudevan SG et al. Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance. Proc Natl Acad Sci USA 2011; 108: 9190-9195.
17. McAlpine SM, Issekutz TB, Marshall JS. Virus stimulation of human mast cells results in the recruitment of CD561 T cells by a mechanism dependent on CCR5 ligands. FASEB J 2012; 26: 1280-1289.
18. Ebert S, Becker M, Lemmermann NA, Buttner JK, Michel A, Taube C et al. Mast cells expedite control of pulmonary murine cytomegalovirus infection by enhancing the recruitment of protective CD8 T cells to the lungs. PLoS Pathog 2014; 10: e1004100.
19. Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34: 258-268.
20. Kambayashi T, Allenspach EJ, Chang JT, Zou T, Shoag JE, Reiner SL et al. Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation. J Immunol 2009; 182: 4686-4695.
21. Stelekati E, Bahri R, DOrlando O, Orinska Z, Mittrucker HW, Langenhaun R et al. Mast cell-mediated antigen presentation regulates CD81 T cell effector functions. Immunity 2009; 31: 665-676.
22. Wang Z, Lai Y, Bernard JJ, Macleod DT, Cogen AL, Moss B et al. Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides. J Immunol 2012; 188: 345-357.
23. Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, Nakao A et al. Mast cells play a key role in host defense against herpes simplex virus infection through TNF-alpha and IL-6 production. J Invest Dermatol 2013; 133: 2170-2179.
24. Davison AJ, Holton M, Dolan A, Dargan DJ, Gatherer D, Hayward GS. Comparative genomics of primate cytomegaloviruses. In: Reddehase MJ (ed.) Cytomegaloviruses: From Molecular Pathogenesis to Intervention. Vo. I. Norfolk: Caister Academic Press, 2013: 1-22.
25. Redwood AJ, Shellam GR, Smith LM. Molecular evolution of murine cytomegalovirus genomes. In: ReddehaseMJ (ed.) Cytomegaloviruses: From Molecular Pathogenesis to Intervention. Vol. I. Norfolk: Caister Academic Press, 2013: 23-37.
26. Ho M. The history of cytomegalovirus and its diseases. Med Microbiol Immunol 2008; 197: 65-73.
27. Boppana SB, Britt WJ. Synopsis of clinical aspects of human cytomegalovirus disease. In: Reddehase MJ (ed.) Cytomegaloviruses: From Molecular Pathogenesis to Intervention. Vol. II. Norfolk: Caister Academic Press, 2013: 1-25.
28. Lyon MF, Glenister PH. A new allele sash (Wsh) at the W-locus and a spontaneous recessive lethal in mice. Genet Res 1982; 39: 315-322.
29. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005; 167: 835-848.
30. Scholten J, Hartmann K, Gerbaulet A, Krieg T, Muller W, Testa G et al. Mast cell-specific Cre/loxP-mediated recombination in vivo. Transgenic Res 2008; 17: 307-315.
31. Mallen-St Clair J, PhamCT, Villalta SA, Caughey GH, Wolters PJ. Mast cell dipeptidyl peptidase I mediates survival from sepsis. J Clin Invest 2004; 113: 628-634.
32. Podlech J, Holtappels R, Grzimek NK, Reddehase MJ. Animal models: murine cytomegalovirus. In: Kaufmann SHE, Kabelitz D (eds.) Methods in Microbiology: Immunology of Infection. 2nd ed. London: Academic Press, 2002: 493-525.
33. Lemmermann NA, Podlech J, Seckert CK, Kropp KA, Grzimek NK, Reddehase MJ et al. CD8 T-cell immunotherapy of cytomegalovirus disease in the murine model. In: Kabelitz D, Kaufmann SHE (eds.) Methods in Microbiology: Immunology of Infection. 3rd ed. London: Academic Press, 2010: 369-420.
34. Wagner M, Jonjic S, Koszinowski UH, Messerle M. Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J Virol 1999; 73: 7056-7060.
35. Bubic I, Wagner M, Krmpotic A, Saulig T, Kim S, YokoyamaWMet al. Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol 2004; 78: 7536-7544.
36. Angulo A, Ghazal P, Messerle M. The major immediate-early gene ie3 of mouse cytomegalovirus is essential for viral growth. J Virol 2000; 74: 11129-11136.
37. Sacher T, Podlech J, Mohr CA, Jordan S, Ruzsics Z, Reddehase MJ et al. The major virus-producing cell type during murine cytomegalovirus infection, the hepatocyte, is not the source of virus dissemination in the host. Cell Host Microbe 2008; 3: 263-272.
38. Erlach KC, Bohm V, Knabe M, Deegen P, Reddehase MJ, Podlech J. Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection. Med Microbiol Immunol 2008; 197: 167-178.
39. Kurz S, Steffens HP, Mayer A, Harris JR, Reddehase MJ. Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol 1997; 71: 2980-2987.
40. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, CrozatKet al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004; 101: 3516-3521.
41. Dalod M, Biron CA. Immunoregulatory cytokine networks discovered and characterized during murine cytomegalovirus infections. In: Reddehase MJ (ed.) Cytomegaloviruses: From Molecular Pathogenesis to Intervention. Vol. II. Norfolk: Caister Academic Press, 2013: 131-257.
42. Vidal S, Krmpotic, A, PyzikM, Jonjic S. Innate immunity to cytomegalovirus in the murine model. In: Reddehase MJ (ed.) Cytomegaloviruses: From Molecular Pathogenesis to Intervention. Vol. II. Norfolk: Caister Academic Press, 2013: 191-213.
43. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002; 296: 1323-1326.
44. Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, Naidenko OV et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci USA 2002; 99: 8826-8831.
45. Stoddart CA, Cardin RD, Boname JM, Manning WC, Abenes GB, Mocarski ES. Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. J Virol 1994; 68: 6243-6253.
46. Sacher T, Jordan S, Mohr CA, Vidy A, Weyn AM, Ruszics Z et al. Conditional gene expression systems to study herpesvirus biology in vivo. Med Microbiol Immunol 2008; 197: 269-276.
47. Lunderius-Andersson C, Enokson M, Nilsson G. Mast cells respond to cell injury through the recognition of IL-33. Front Immunol 2012; 3: 82.
48. Delale T, Paquin A, Asselin-Paturel C, Dalod M, Brizard G, Bates EE et al. MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J Immunol 2005; 175: 6723-6732.
49. Yung S, Chan TM. Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells. Mediators Inflamm 2012; 2012: 484167.
50. Edelmann KH, Richardson-Burns S, Alexopoulou L, Tyler KL, Flavell RA, Oldstone MB. Does Toll-like receptor 3 play a biological role in virus infections? Virology 2004; 322: 231-238.
51. Gilfillan AM, Beaven MA. Regulation of mast cell responses in health and disease. Crit Rev Immunol 2011; 31: 475-529.
52. Schafer T, Starkl P, Allard C, Wolf RM, Schweighoffer T. A granular variant of CD63 is a regulator of repeated human mast cell degranulation. Allergy 2010; 65: 1242-1255.